EGFR and interstitial lung disease: The prevalence and severity of other AEs, including interstitial lung disease (ILD) and liver function impairments that have been considered idiosyncratic and are usually not linked to the effectiveness of EGFR inhibition, are correlated with the potency of EGFR inhibition.